Attovia Therapeutics, Inc. reported that Chief Scientific Officer Petter Veiby received a grant of stock options covering 140,000 shares of common stock at an exercise price of $17.00 per share. The options expire on August 3, 2036 and vest 25% on August 4, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, subject to continued service. Following this award, Veiby holds options on 140,000 shares directly.
Attovia Therapeutics, Inc. reported that Chief Medical Officer Chen Hubert received a grant of stock options covering 140,000 shares of common stock on August 4, 2026. The options have an exercise price of $17.00 per share and expire on August 3, 2036. Following this grant, Hubert holds 140,000 options directly. According to the vesting terms, 25% of the options vest on August 4, 2027, with the remaining options vesting in equal monthly installments over the subsequent 36 months, subject to continued service.
Attovia Therapeutics, Inc. reported a grant of stock options to its Chief Financial Officer. The grant covers 140,000 Stock Options (Right to Buy) with an exercise price of $17.00 per share, expiring on August 3, 2036, and represents 140,000 options held after the transaction. The options relate to an equivalent number of shares of common stock.
According to the vesting terms, 25% of the options will vest on August 4, 2027, with the remaining options vesting in equal monthly installments over the following 36 months, contingent on continued service to the company.
Attovia Therapeutics, Inc. reported a grant of stock options covering 538,300 shares of common stock with an exercise price of $17.00 per share. The options expire on August 3, 2036. According to the vesting schedule, 25% vests on August 4, 2027, with the remainder vesting in equal monthly installments over the following 36 months, subject to continued service.
Attovia Therapeutics, Inc. implemented an Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws on August 6, 2026, in connection with the closing of its initial public offering of common stock, par value $0.0001 per share. The board of directors and stockholders had previously approved these revised governing documents to become effective immediately prior to the offering’s closing, as described in the company’s final prospectus dated August 4, 2026. The company’s common stock trades under the symbol ATTO on the Nasdaq Global Market.
Alamar HoldCo, LLC reported its initial beneficial ownership in Attovia Therapeutics, Inc. as a more than 10% holder on Form 3. The entity holds 3,229,278 shares of Common Stock directly. The remarks state that, in connection with the closing of Attovia’s initial public offering, Alamar HoldCo will cease to be a 10% holder.
Attovia Therapeutics, Inc. director Colin Walsh reported initial indirect holdings of the company’s preferred stock. The filing lists Series B Preferred Stock convertible into 1,957,140 shares of common stock and Series C Preferred Stock convertible into 478,501 shares of common stock, all held through Goldman Sachs–affiliated investment vehicles. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.
Attovia Therapeutics, Inc. is conducting an initial public offering of 17,000,000 shares of common stock at $17.00 per share, for a gross offering of $289,000,000. Underwriters have a 30-day option to purchase up to 2,550,000 additional shares to cover over-allotments. Net proceeds are estimated at $265.1 million (or $305.4 million with full exercise), after underwriting discounts and estimated expenses.
The company is a clinical-stage biopharmaceutical developer of next‑generation biologics for immune‑mediated diseases, built on its proprietary ATTOBODY platform. Lead candidate ATTO-1310 is in a Phase 1 trial for chronic pruritic diseases; ATTO-2306 (bispecific IL‑13/IL‑31) and ATTO-1091 (trispecific TL1A/IL‑23/integrin α4β7) are in IND‑enabling studies with planned Phase 1 trials in the first half of 2027.
As of March 31, 2026, Attovia held $132.6 million in cash, cash equivalents and marketable securities and reported an accumulated deficit of $129.7 million, reflecting net losses of $39.8 million in 2024 and $60.6 million in 2025. The company qualifies as an emerging growth company and smaller reporting company and expects the IPO proceeds, together with existing cash, to fund operations into 2029.
Attovia Therapeutics, Inc. reports that Deep Track Biotechnology Master Fund, Ltd., together with affiliated entities Deep Track Capital, LP and David Kroin, has an initial reported position in Series C Redeemable Convertible Preferred Stock. This preferred stock is convertible into 1,957,138 shares of common stock at a fixed 9.29-for-one conversion ratio and has no expiration date. The preferred shares are held by Deep Track Biotechnology Master Fund, Ltd., with Deep Track Capital, LP as investment manager and David Kroin as managing member of the general partner; the latter two disclaim beneficial ownership except to the extent of their pecuniary interests.
Redmile Group, LLC and affiliated entities report initial beneficial ownership in Attovia Therapeutics, Inc. through holdings of Series B Preferred Stock. This preferred stock is convertible into 782,854 shares of common stock and is held indirectly via Redmile Biopharma Investments III, L.P.
The Series B Preferred Stock is convertible into common stock for no consideration at any time at the holder's election or automatically upon the closing of Attovia's initial public offering, and is redeemable at the holder's option beginning in March 2035 at the applicable original issue price plus declared but unpaid dividends. The security has no expiration date. A prior 1-for-9.29 reverse stock split of Attovia's common stock was effected on July 29, 2026. The reporting persons state that they may be deemed beneficial owners through investment management relationships and disclaim beneficial ownership beyond any pecuniary interest.